Theravance Biopharma Financial Ratios Analysis

Valuation, profitability, leverage, and liquidity ratios

Scroll to see more
BreakdownFY 2024FY 2023FY 2022FY 2021FY 2020
Period EndingDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Valuation Ratios
P/E Ratio0.86
P/S Ratio7.199.7514.7014.7215.82
P/B Ratio2.642.631.71-2.40-3.74
Price/Tangible Book2.642.631.71
Enterprise Value Ratios
EV/Revenue6.478.306.2322.9519.46
Profitability & Returns
Return on Equity (ROE)-0.29%-0.17%-1.80%
Return on Assets (ROA)-0.07%-0.07%-0.10%-0.35%-0.42%
Return on Capital Employed (ROCE)-0.13%-0.15%-0.14%-0.75%-0.86%
Leverage & Solvency Ratios
Debt/Equity0.280.230.12-1.98-2.23
Liquidity Ratios
Current Ratio5.025.3912.314.263.18
Quick Ratio4.894.8411.993.202.93
Efficiency Ratios
Asset Turnover0.170.120.100.130.16
Yield & Distribution Ratios
Earnings Yield-0.12%-0.10%1.16%-0.24%-0.24%
FCF Yield-0.03%-0.05%-0.25%-0.26%-0.23%
Buyback Yield0.12%0.25%-0.06%-0.11%-0.12%